Vaxxas
PrivateLast Round
Debt
Aug 25, 2025
Est. Valuation
$805M
Total Funding Raised
$189.22M
Momentum Score
25 /100
Company Overview
Vaxxas is a biotechnology company developing a needle-free, patch-based vaccine delivery technology to improve vaccine performance and stability.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Hardware Sales, Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vaxxas Comps
Public and private peers based on sector, stage, and business model.
Vaxxas Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Aug 25, 2025 | ||||
| Series D | Aug 25, 2025 | ||||
| Grant | Jan 22, 2025 | ||||
| VC Round | Dec 5, 2022 | ||||
| Series C | May 28, 2020 | ||||
Series B | Apr 1, 2017 |
Key People
Founding team and executive leadership
Vaxxas Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UniQuest Pty Ltd | VC Round |
| OneVentures | Series D, Series A, VC Round, Series B |
| CEPI | Grant |
| Medical Research Commercialisation Fund | Series A, Series B |
| HealthCare Ventures | Series A, Series B |
| SPRIM Global Investments | Series D, Debt |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 7, 2026
David Peacock appointed as new CEO to lead commercialization.
- Nov 10, 2025
Brent MacGregor, veteran vaccine executive, joins the Board of Directors.
Vaxxas Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Vaxxas's valuation, stock price, and market status.
